Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) was selected as a StartUp Health Alzheimer’s & Brain Health Moonshot company and will participate in StartUp Health Apollo House during JPM Healthcare Week in January 2026. Apollo House is a founders-and-funders networking summit focused on Health Moonshots for Alzheimer’s, Parkinson’s and related conditions, supported by champions including the Alzheimer’s Drug Discovery Foundation and Gates Ventures.
Longeveron said it will host meetings with institutional investors and potential partners during the week; investors may request meetings by contacting info@longeveron.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, LGVN declined 2.91%, reflecting a moderate negative market reaction. This price movement removed approximately $331K from the company's valuation, bringing the market cap to $11M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Within Biotechnology peers, moves were mixed pre-news: EDSA up 11.63%, NBY up 3.19%, PULM up 2.63%, SYBX up 1.68%, while MTVA was down 6.32%. Momentum scanner only flagged THAR up 4.25%, suggesting LGVN’s setup was stock-specific rather than part of a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Patent grant (US) | Positive | +7.8% | New U.S. patent on MSC therapy for female sexual dysfunction through 2038. |
| Dec 03 | Conference participation | Positive | -1.2% | Executives speaking at CVCT Forum on cell therapy for heart failure. |
| Dec 02 | Patent grant (Canada) | Positive | +2.2% | Canadian patent for laromestrocel use in frailty and NIDCM to 2037. |
| Dec 01 | Alzheimer’s MRI data | Positive | -5.1% | Phase 2 CLEAR MIND MRI biomarker data with significant p-values at CTAD. |
| Nov 19 | Conference poster | Positive | -4.0% | Laromestrocel Alzheimer’s poster selection for CTAD 2025 conference. |
Recent history shows mixed reactions, with several positive scientific or patent updates followed by negative or muted price moves, and occasional strong gains on IP news.
Over the past months, Longeveron reported multiple developments spanning Alzheimer’s disease and aging-related indications. On Nov 19, 2025 and Dec 1–4, 2025, laromestrocel (Lomecel-B) Alzheimer’s data and CTAD presentations highlighted MRI biomarker and poster recognition. Canadian and U.S. patents granted in 2025 expanded protection into female sexual dysfunction, frailty, and NIDCM, with one patent driving a 7.81% gain. Conference appearances and scientific visibility have not consistently translated into positive price moves, framing today’s JPM Healthcare Week participation as a continuation of that visibility strategy.
Market Pulse Summary
This announcement highlights Longeveron’s role in the StartUp Health Alzheimer’s & Brain Health Moonshot community and its planned participation in Apollo House during JPM Healthcare Week 2026, alongside meetings with institutional investors and potential partners. Set against recent Alzheimer’s MRI biomarker data and new patents in frailty and female sexual dysfunction, it underscores management’s focus on visibility and collaboration. Investors may watch for future updates on clinical progression, financing plans, and any partnerships that emerge from these meetings.
Key Terms
cellular therapy medical
alzheimer’s disease medical
parkinson’s disease medical
AI-generated analysis. Not financial advice.
- Mission-aligned community focused on accelerating breakthroughs in Alzheimer’s disease, Parkinson’s disease and related conditions
- Supported by Health Moonshot Champions, including the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates Ventures
- Apollo House, the Founders & Funders Networking Summit, to bring together founders, funders and industry leaders addressing Health Moonshots worldwide
- Longeveron will also be hosting meetings with institutional investors and potential partners during the week
MIAMI, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that, as a StartUp Health Alzheimer’s & Brain Health Moonshot company, it will be participating in StartUp Health Apollo House during JPM Healthcare Week in January 2026.
StartUp Health Alzheimer’s & Brain Moonshot is a mission-aligned community focused on accelerating breakthroughs in Alzheimer’s disease, Parkinson’s disease and related conditions, supported by Health Moonshot Champions, including the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates Ventures. Apollo House, the Founders & Funders Networking Summit, is intended to bring together founders, funders and industry leaders addressing Health Moonshots worldwide.
Longeveron will also be hosting meetings with institutional investors and potential partners during JPM Healthcare Week. Please contact info@longeveron.com to schedule a meeting with members of Longeveron’s senior management.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
What will Longeveron (LGVN) be doing at JPM Healthcare Week January 2026?
When and where is Longeveron scheduled to attend StartUp Health Apollo House for JPM 2026?
How can investors schedule a meeting with Longeveron (LGVN) at JPM Healthcare Week 2026?
What is StartUp Health Apollo House and who supports the Alzheimer’s Moonshot community?
Does Longeveron’s announcement on Dec. 29, 2025 include financial or clinical data?
